CCR4 and liver cancer: Moreover, interfering with a CCR4 antagonist or a N-terminus recombinant protein of CCR4 (N-CCR4-Fc) exerts a prominent effect on conquering sorafenib resistance and sensitizes liver cancer to PD-1 checkpoint inhibitor (Gao et al., 2022).